Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose

E P Van Puijenbroek; H J Metselaar; P H Berghuis; P E Zondervan; B H Stricker

Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose

Translated title of the contribution: Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects

E P Van Puijenbroek, H J Metselaar, P H Berghuis, P E Zondervan, B H Stricker

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

The imidazole derivative ketoconazole is approved in the Netherlands for treatment of local and systemic fungal infections. Despite the risk of major hepatic damage, this antimycotic drug is still being used in daily practice for the oral treatment of patients with onychomycosis. Since April 1986, 18 cases of relatively severe hepatic damage in the Netherlands were ascribed to the oral use of ketoconazole for the treatment of onychomycosis, skin infection or vaginal candidiasis. Given the potential risk for the patients concerned, ketoconazole should no longer be prescribed for relatively mild cosmetic disorders such as onychomycosis.

Translated title of the contribution	Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects
Original language	Dutch
Pages (from-to)	2416-2418
Number of pages	3
Journal	Nederlands Tijdschrift voor de Geneeskunde
Volume	142
Issue number	44
Publication status	Published - 31-Oct-1998

Keywords

Adolescent
Adult
Adverse Drug Reaction Reporting Systems
Aged
Antifungal Agents
Drug-Induced Liver Injury
Female
Humans
Incidence
Ketoconazole
Liver
Male
Middle Aged
Necrosis
Netherlands
Onychomycosis
Survival Rate

Handle.net

Persistent link

Cite this

@article{9db89ed1dc1a4e008de229ce60713a7e,

title = "Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose",

abstract = "The imidazole derivative ketoconazole is approved in the Netherlands for treatment of local and systemic fungal infections. Despite the risk of major hepatic damage, this antimycotic drug is still being used in daily practice for the oral treatment of patients with onychomycosis. Since April 1986, 18 cases of relatively severe hepatic damage in the Netherlands were ascribed to the oral use of ketoconazole for the treatment of onychomycosis, skin infection or vaginal candidiasis. Given the potential risk for the patients concerned, ketoconazole should no longer be prescribed for relatively mild cosmetic disorders such as onychomycosis.",

keywords = "Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Antifungal Agents, Drug-Induced Liver Injury, Female, Humans, Incidence, Ketoconazole, Liver, Male, Middle Aged, Necrosis, Netherlands, Onychomycosis, Survival Rate",

author = "{Van Puijenbroek}, {E P} and Metselaar, {H J} and Berghuis, {P H} and Zondervan, {P E} and Stricker, {B H}",

year = "1998",

month = oct,

day = "31",

language = "Dutch",

volume = "142",

pages = "2416--2418",

journal = "Nederlands Tijdschrift voor de Geneeskunde",

issn = "0028-2162",

publisher = "NLM (Medline)",

number = "44",

}

TY - JOUR

T1 - Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose

AU - Van Puijenbroek, E P

AU - Metselaar, H J

AU - Berghuis, P H

AU - Zondervan, P E

AU - Stricker, B H

PY - 1998/10/31

Y1 - 1998/10/31

N2 - The imidazole derivative ketoconazole is approved in the Netherlands for treatment of local and systemic fungal infections. Despite the risk of major hepatic damage, this antimycotic drug is still being used in daily practice for the oral treatment of patients with onychomycosis. Since April 1986, 18 cases of relatively severe hepatic damage in the Netherlands were ascribed to the oral use of ketoconazole for the treatment of onychomycosis, skin infection or vaginal candidiasis. Given the potential risk for the patients concerned, ketoconazole should no longer be prescribed for relatively mild cosmetic disorders such as onychomycosis.

AB - The imidazole derivative ketoconazole is approved in the Netherlands for treatment of local and systemic fungal infections. Despite the risk of major hepatic damage, this antimycotic drug is still being used in daily practice for the oral treatment of patients with onychomycosis. Since April 1986, 18 cases of relatively severe hepatic damage in the Netherlands were ascribed to the oral use of ketoconazole for the treatment of onychomycosis, skin infection or vaginal candidiasis. Given the potential risk for the patients concerned, ketoconazole should no longer be prescribed for relatively mild cosmetic disorders such as onychomycosis.

KW - Adolescent

KW - Adult

KW - Adverse Drug Reaction Reporting Systems

KW - Aged

KW - Antifungal Agents

KW - Drug-Induced Liver Injury

KW - Female

KW - Humans

KW - Incidence

KW - Ketoconazole

KW - Liver

KW - Male

KW - Middle Aged

KW - Necrosis

KW - Netherlands

KW - Onychomycosis

KW - Survival Rate

M3 - Article

C2 - 9864540

SN - 0028-2162

VL - 142

SP - 2416

EP - 2418

JO - Nederlands Tijdschrift voor de Geneeskunde

JF - Nederlands Tijdschrift voor de Geneeskunde

IS - 44

ER -

Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose

Abstract

Keywords

Handle.net

Fingerprint

Cite this